Latest News
Low Insulin Costs on the Horizon?
Diabetes, one of the most prevalent healthcare issues faced by American seniors, often carries with it pretty steep costs related to the insulin drugs needed to combat the disease. Of course, lowering the costs of prescription medications is in the spotlight in this election year, but now some action is actually being taken to at least provide relief to diabetics who rely on insulin. The Trump Administration has put forth a new pilot program to cap insulin costs at $35 per month, and many drug manufacturers are supportive of the idea. This New York Times article by Katie Thomas explains how the pilot program would work and how the major drug manufacturers have, mostly positively, reacted to it. Click here to read more.
This posting is presented for informational purposes only and does not represent legal or financial guidance. Any opinions or interpretations presented are either those of the original author or, in the case of articles authored by the AMAC Foundation, are the opinions of AMAC Foundation staff, originally trained and accredited by the National Social Security Association (NSSA) and certified via the AMAC Foundation. Any links included in the article are valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the links’ validity. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (https://amacfoundation.org/services/) or email us at ssadvisor@amacfoundation.org. Because we are a non-profit organization, there is no charge for these services.